Key statistics
On Friday, Tempest Therapeutics Inc (TPST:NAQ) closed at 2.28, 7.55% above its 52-week low of 2.12, set on Feb 25, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.22 |
|---|---|
| High | 2.28 |
| Low | 2.20 |
| Bid | 1.90 |
| Offer | 2.33 |
| Previous close | 2.29 |
| Average volume | 98.34k |
|---|---|
| Shares outstanding | 13.20m |
| Free float | 8.35m |
| P/E (TTM) | -- |
| Market cap | 30.09m USD |
| EPS (TTM) | -10.40 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 21:00 GMT.
More ▼
- Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
- Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
- Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
- Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
- Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
- Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
- Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
- Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
- Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
- Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
More ▼
